Developer docs
API playgroundTry for free, no card

Search company profiles

INNOVENTRIC

Full company profile

uuid0002djn

Namestring
INNOVENTRIC
Legal namestring
Innoventric Ltd.
Websiteurl
innoventric.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Innoventric Ltd. is a privately held Israeli medical device company founded in 2016/2017 in the Ness-Ziona/Rehovot area, developing transcatheter systems to treat tricuspid regurgitation (TR). The company's core innovation is a cross-caval heterotopic approach that deploys valve implants in the superior and inferior vena cava (SVC and IVC) rather than replacing or repairing the tricuspid valve itself, enabling treatment of patients with severe or torrential TR who are ineligible for transcatheter edge-to-edge repair (TEER), orthotopic transcatheter tricuspid valve replacement (TTVR), or bi-caval valve replacement. The portfolio comprises three devices: Trillium™, a multi-valve device with a flexible hinge design optimized for large and tortuous anatomies; Koala™, a cross-caval docking station for anchoring off-the-shelf valves in the SVC and IVC; and Unica™, an anatomy-agnostic single-stent, double-valve implant on a 26 Fr delivery system designed for venous transfemoral access, sub-10-minute device time, conscious sedation compatibility (no TEE or general anesthesia required), and future valve-in-valve or transseptal re-intervention. Reported technical performance includes 600M-cycle durability testing with no fractures, migration-resistant anchoring, and immediate hemodynamic improvements (V-wave CVP reduction of 12 mmHg and cardiac output increase from 6 to 9.6 L/min in first US EFS case).

Innoventric's business model is clinical-stage hardware sales delivered through FDA-approved IDE Early Feasibility Studies, compassionate use programs, and First-in-Human clinical investigations. Distribution is direct to interventional cardiology departments at leading cardiac centers across the US, Germany, Belgium, Spain, Israel, Canada, France, Italy, and Georgia, with go-to-market executed via clinical investigator engagement and medical conference dissemination rather than conventional field sales. Pricing is not publicly disclosed; the company has recognized no commercial revenue to date, with funding of approximately $48M cumulatively sourced from a €2.5M Horizon Europe grant (Nov 2021), a $14M Series A (Nov 2021), and a $28.5M Series B (Oct 2024, led by RA Capital Management). The company holds over 50 granted cardiovascular patents and is led by founder/CEO Amir Danino (inventor of the technology) and co-founders Rafi Benary (previously founded Ventor Technologies, acquired by Medtronic in 2009) and Dr. David Planer (Head of Interventional Cardiology at Hadassah Medical Center).

The served customer base is concentrated in academic and high-volume cardiac centers performing structural heart interventions, with named clinical collaborators including TriStar Centennial Medical Center (Nashville), St. Michael's Hospital Toronto, Hadassah Medical Center, Leipzig Heart Center, and Hospital Alvaro Cunqueiro (Vigo). Customer segments are the patients with tricuspid regurgitation previously deemed untreatable by other interventional therapies, and the interventional cardiology centers seeking an anatomy-agnostic TR solution compatible with conscious sedation and short procedure times. Regulatory milestones include FDA IDE approval for the Trillium EFS (December 2023), completion of European/Israeli FIH enrollment at 20 patients with 2.5-year follow-up (July 2023), and completion of 15-patient US/German EFS enrollment (September 2025), with extended enrollment announced November 2025.

Short descriptiontext

Innoventric is a Rehovot, Israel-based clinical-stage medical device company developing transcatheter cross-caval heterotopic valve implants (Trillium, Koala, Unica) to treat tricuspid regurgitation in patients ineligible for TEER or orthotopic TTVR, currently delivering devices through FDA IDE Early Feasibility Studies and compassionate use programs at leading cardiac centers across the US, Europe, Israel, and Canada.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRehovot, Israel
HQ citystring
Rehovot
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcatheter valve replacement, tricuspid regurgitation treatment, structural heart devices, catheter-delivered implants, interventional cardiology devices
Industry2 codes
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHADAM
Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Transcatheter Heart Valve Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Revenue generated from sale of transcatheter valve replacement devices (Trillium, Koala, Unica) to hospitals and cardiac centers. Currently available through clinical trials and compassionate use programs. Future commercial launch will expand direct hospital sales.

innoventric.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Trillium
Description

First-of-its-kind cross-caval device for treating tricuspid regurgitation (TR) in a broad patient population. Features multiple valves with a novel hinge design, beneficial for large and tortuous anatomies.

innoventric.com
+2 more records
Core offering1 text field

Innoventric designs, develops, and manufactures transcatheter tricuspid regurgitation (TR) treatment devices using a proprietary cross-caval heterotopic approach. The company sells three flagship implant systems — Trillium™, Koala™, and Unica™ — to interventional cardiology departments at hospitals and cardiac centers, currently delivered through clinical trials and compassionate use programs ahead of broader commercial launch.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Cardiac output increase from 6 L/min to 9.6 L/min observed in first US EFS patient
+5 more records
Product overview1 text field

Innoventric develops transcatheter tricuspid regurgitation (TR) solutions using a cross-caval heterotopic approach. The company's portfolio includes three core devices: Trillium™ (the first cross-caval device with multiple valves and novel hinge design for large/tortuous anatomies), Koala™ (a docking station for anchoring off-the-shelf valves in SVC and IVC), and Unica™ (an anatomy-agnostic implant with bare metal structure and intra-luminal valves for broader patient population including smaller anatomies). All devices employ a heterotopic approach that targets the caval system rather than the valve itself, enabling treatment of patients previously considered untreatable. The Unica™ features a 26 Fr low-profile delivery system and is designed for less than 10 minutes device implantation time with conscious sedation, eliminating the need for TEE or general anesthesia.

Product and service3 records
1Trillium™
CategoryTranscatheter Heart Valve Devices
Description

First-of-its-kind cross-caval transcatheter device for tricuspid regurgitation, featuring multiple valves with a novel hinge design and intended for a broad patient population, including those with large and tortuous anatomies. Device implantation time is under 10 minutes, with secure migration-resistant positioning and reliable sealing.

2Koala™
CategoryTranscatheter Heart Valve Devices
Description

Cross-caval docking station designed to anchor in both the SVC and IVC and facilitate placement of an off-the-shelf valve for tricuspid regurgitation treatment. Several compassionate cases have been performed in the EU.

3Unica™
CategoryTranscatheter Heart Valve Devices
Description

Anatomy-agnostic single-stent, double-valve heterotopic cross-caval implant for safe and effective TR treatment, extending care to a broader patient population including those with smaller anatomies. Features a bare-metal center structure enabling future transseptal procedures and intra-luminal valves supporting future valve-in-valve procedures, secured to SVC and IVC with migration-resistant anchoring. Delivered via a 26 Fr low-profile venous transfemoral system under conscious sedation without TEE or general anesthesia. Compassionate use cases performed in the EU and Canada.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global structural heart leader with PASCAL transcatheter tricuspid repair and Evoque TTVR programs. Directly competes in TR with multiple modalities and vastly larger commercial infrastructure.

TypeBroad incumbent
Description

Acquired Ventor Technologies (founded by Innoventric co-founder Rafi Benary) in 2009 and has a long-standing structural heart presence. A natural strategic acquirer of transcatheter valve innovation.

TypeEmerging player
Description

Developer of the Carillon System for tricuspid and mitral functional regurgitation via coronary sinus annuloplasty. Competes with Innoventric in the transcatheter TR treatment market with a different mechanism.

4Abbott
TypeBroad incumbent
Description

Markets TriClip, the first FDA-approved transcatheter tricuspid TEER device, and is developing orthotopic TTVR options. Competes with Innoventric for the same patient population and cardiology KOL relationships.

5Polares Medical
TypeEmerging player
Description

Spin-off from Halfmoon Medical (acquired by Edwards Lifesciences) developing a transcatheter tricuspid valve replacement technology. Direct overlap with Innoventric in orthotopic-style TR replacement.

TypeEmerging player
Description

Structural heart company developing the DurAVR transcatheter heart valve system with proprietary 3D-shaped valve technology. Comparable as a clinical-stage transcatheter valve developer targeting structural heart indications.

TypeEmerging player
Description

Developed a transcatheter tricuspid and mitral valve replacement system (now part of Venus Medtech). Direct overlap with Innoventric in transcatheter valve replacement for tricuspid regurgitation.

TypeEmerging player
Description

Develops transcatheter mitral and tricuspid valve technologies including AltaValve, an supra-annular system. Competes in the structural heart replacement space adjacent to Innoventric's TR focus.

TypeEmerging player
Description

Early-stage Irish company developing a transcatheter tricuspid coaptation valve, addressing a similar patient population as Innoventric via a different anchoring mechanism.

10Venus Medtech
TypeEmerging player
Description

Chinese structural heart company that acquired Cardiovalve, a transcatheter tricuspid and mitral valve developer. Competes with Innoventric in transcatheter TR with both repair and replacement approaches.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

INNOVENTRIC

Transcatheter Heart Valve Devicesinnoventric.com

Innoventric is a Rehovot, Israel-based clinical-stage medical device company developing transcatheter cross-caval heterotopic valve implants (Trillium, Koala, Unica) to treat tricuspid regurgitation in patients ineligible for TEER or orthotopic TTVR, currently delivering devices through FDA IDE Early Feasibility Studies and compassionate use programs at leading cardiac centers across the US, Europe, Israel, and Canada.

What INNOVENTRIC does

Innoventric Ltd. is a privately held Israeli medical device company founded in 2016/2017 in the Ness-Ziona/Rehovot area, developing transcatheter systems to treat tricuspid regurgitation (TR). The company's core innovation is a cross-caval heterotopic approach that deploys valve implants in the superior and inferior vena cava (SVC and IVC) rather than replacing or repairing the tricuspid valve itself, enabling treatment of patients with severe or torrential TR who are ineligible for transcatheter edge-to-edge repair (TEER), orthotopic transcatheter tricuspid valve replacement (TTVR), or bi-caval valve replacement. The portfolio comprises three devices: Trillium™, a multi-valve device with a flexible hinge design optimized for large and tortuous anatomies; Koala™, a cross-caval docking station for anchoring off-the-shelf valves in the SVC and IVC; and Unica™, an anatomy-agnostic single-stent, double-valve implant on a 26 Fr delivery system designed for venous transfemoral access, sub-10-minute device time, conscious sedation compatibility (no TEE or general anesthesia required), and future valve-in-valve or transseptal re-intervention. Reported technical performance includes 600M-cycle durability testing with no fractures, migration-resistant anchoring, and immediate hemodynamic improvements (V-wave CVP reduction of 12 mmHg and cardiac output increase from 6 to 9.6 L/min in first US EFS case).

Innoventric's business model is clinical-stage hardware sales delivered through FDA-approved IDE Early Feasibility Studies, compassionate use programs, and First-in-Human clinical investigations. Distribution is direct to interventional cardiology departments at leading cardiac centers across the US, Germany, Belgium, Spain, Israel, Canada, France, Italy, and Georgia, with go-to-market executed via clinical investigator engagement and medical conference dissemination rather than conventional field sales. Pricing is not publicly disclosed; the company has recognized no commercial revenue to date, with funding of approximately $48M cumulatively sourced from a €2.5M Horizon Europe grant (Nov 2021), a $14M Series A (Nov 2021), and a $28.5M Series B (Oct 2024, led by RA Capital Management). The company holds over 50 granted cardiovascular patents and is led by founder/CEO Amir Danino (inventor of the technology) and co-founders Rafi Benary (previously founded Ventor Technologies, acquired by Medtronic in 2009) and Dr. David Planer (Head of Interventional Cardiology at Hadassah Medical Center).

The served customer base is concentrated in academic and high-volume cardiac centers performing structural heart interventions, with named clinical collaborators including TriStar Centennial Medical Center (Nashville), St. Michael's Hospital Toronto, Hadassah Medical Center, Leipzig Heart Center, and Hospital Alvaro Cunqueiro (Vigo). Customer segments are the patients with tricuspid regurgitation previously deemed untreatable by other interventional therapies, and the interventional cardiology centers seeking an anatomy-agnostic TR solution compatible with conscious sedation and short procedure times. Regulatory milestones include FDA IDE approval for the Trillium EFS (December 2023), completion of European/Israeli FIH enrollment at 20 patients with 2.5-year follow-up (July 2023), and completion of 15-patient US/German EFS enrollment (September 2025), with extended enrollment announced November 2025.

INNOVENTRIC firmographics

Firmographics
Name
INNOVENTRIC
Legal name
Innoventric Ltd.
Website
https://innoventric.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Innoventric is a Rehovot, Israel-based clinical-stage medical device company developing transcatheter cross-caval heterotopic valve implants (Trillium, Koala, Unica) to treat tricuspid regurgitation in patients ineligible for TEER or orthotopic TTVR, currently delivering devices through FDA IDE Early Feasibility Studies and compassionate use programs at leading cardiac centers across the US, Europe, Israel, and Canada.
Ownership category
akta.pro rank

INNOVENTRIC industry classification

Industry
Product category
Transcatheter Heart Valve Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHADAM
Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Transcatheter valve replacement
  • Tricuspid regurgitation treatment
  • Structural heart devices
  • Catheter-delivered implants
  • Interventional cardiology devices

Where INNOVENTRIC is headquartered

Location

Headquarters

HQ city
Rehovot
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

INNOVENTRIC business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Medical Device Sales: Revenue generated from sale of transcatheter valve replacement devices (Trillium, Koala, Unica) to hospitals and cardiac centers. Currently available through clinical trials and compassionate use programs. Future commercial launch will expand direct hospital sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

INNOVENTRIC product offering

Product offering

Core offering

Innoventric designs, develops, and manufactures transcatheter tricuspid regurgitation (TR) treatment devices using a proprietary cross-caval heterotopic approach. The company sells three flagship implant systems — Trillium™, Koala™, and Unica™ — to interventional cardiology departments at hospitals and cardiac centers, currently delivered through clinical trials and compassionate use programs ahead of broader commercial launch.

Product overview

Innoventric develops transcatheter tricuspid regurgitation (TR) solutions using a cross-caval heterotopic approach. The company's portfolio includes three core devices: Trillium™ (the first cross-caval device with multiple valves and novel hinge design for large/tortuous anatomies), Koala™ (a docking station for anchoring off-the-shelf valves in SVC and IVC), and Unica™ (an anatomy-agnostic implant with bare metal structure and intra-luminal valves for broader patient population including smaller anatomies). All devices employ a heterotopic approach that targets the caval system rather than the valve itself, enabling treatment of patients previously considered untreatable. The Unica™ features a 26 Fr low-profile delivery system and is designed for less than 10 minutes device implantation time with conscious sedation, eliminating the need for TEE or general anesthesia.

Differentiator

Problem solved

Functional benefit

Brands

  • Trillium: First-of-its-kind cross-caval device for treating tricuspid regurgitation (TR) in a broad patient population. Features multiple valves with a novel hinge design, beneficial for large and tortuous anatomies.
  • Koala
  • Unica

Products and services

  • Trillium™ First-of-its-kind cross-caval transcatheter device for tricuspid regurgitation, featuring multiple valves with a novel hinge design and intended for a broad patient population, including those with large and tortuous anatomies. Device implantation time is under 10 minutes, with secure migration-resistant positioning and reliable sealing.
  • Koala™ Cross-caval docking station designed to anchor in both the SVC and IVC and facilitate placement of an off-the-shelf valve for tricuspid regurgitation treatment. Several compassionate cases have been performed in the EU.
  • Unica™ Anatomy-agnostic single-stent, double-valve heterotopic cross-caval implant for safe and effective TR treatment, extending care to a broader patient population including those with smaller anatomies. Features a bare-metal center structure enabling future transseptal procedures and intra-luminal valves supporting future valve-in-valve procedures, secured to SVC and IVC with migration-resistant anchoring. Delivered via a 26 Fr low-profile venous transfemoral system under conscious sedation without TEE or general anesthesia. Compassionate use cases performed in the EU and Canada.

Quantifiable outcome

  • Cardiac output increase from 6 L/min to 9.6 L/min observed in first US EFS patient
  • +5 more outcomes

Companies that use INNOVENTRIC

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles1 record

INNOVENTRIC technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

INNOVENTRIC partnerships and signals

Strategic signal

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

INNOVENTRIC competitors and assessment

Company assessment

Broad incumbents

  • Edwards Lifesciences: Global structural heart leader with PASCAL transcatheter tricuspid repair and Evoque TTVR programs. Directly competes in TR with multiple modalities and vastly larger commercial infrastructure.
  • Medtronic: Acquired Ventor Technologies (founded by Innoventric co-founder Rafi Benary) in 2009 and has a long-standing structural heart presence. A natural strategic acquirer of transcatheter valve innovation.
  • Abbott: Markets TriClip, the first FDA-approved transcatheter tricuspid TEER device, and is developing orthotopic TTVR options. Competes with Innoventric for the same patient population and cardiology KOL relationships.

Emerging players

  • Cardiac Dimensions: Developer of the Carillon System for tricuspid and mitral functional regurgitation via coronary sinus annuloplasty. Competes with Innoventric in the transcatheter TR treatment market with a different mechanism.
  • Polares Medical: Spin-off from Halfmoon Medical (acquired by Edwards Lifesciences) developing a transcatheter tricuspid valve replacement technology. Direct overlap with Innoventric in orthotopic-style TR replacement.
  • Anteris Technologies: Structural heart company developing the DurAVR transcatheter heart valve system with proprietary 3D-shaped valve technology. Comparable as a clinical-stage transcatheter valve developer targeting structural heart indications.
  • Cardiovalve: Developed a transcatheter tricuspid and mitral valve replacement system (now part of Venus Medtech). Direct overlap with Innoventric in transcatheter valve replacement for tricuspid regurgitation.
  • 4C Medical Technologies: Develops transcatheter mitral and tricuspid valve technologies including AltaValve, an supra-annular system. Competes in the structural heart replacement space adjacent to Innoventric's TR focus.
  • CroíValve: Early-stage Irish company developing a transcatheter tricuspid coaptation valve, addressing a similar patient population as Innoventric via a different anchoring mechanism.
  • Venus Medtech: Chinese structural heart company that acquired Cardiovalve, a transcatheter tricuspid and mitral valve developer. Competes with Innoventric in transcatheter TR with both repair and replacement approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

INNOVENTRIC social profiles

Digital presence

INNOVENTRIC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

INNOVENTRIC leadership team

Management profile

Number of profiles

Profiles11 records

INNOVENTRIC funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

INNOVENTRIC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INNOVENTRIC

What does INNOVENTRIC do?

Innoventric designs, develops, and manufactures transcatheter tricuspid regurgitation (TR) treatment devices using a proprietary cross-caval heterotopic approach. The company sells three flagship implant systems — Trillium™, Koala™, and Unica™ — to interventional cardiology departments at hospitals and cardiac centers, currently delivered through clinical trials and compassionate use programs ahead of broader commercial launch.

Is INNOVENTRIC a public or private company?

INNOVENTRIC is a private company. It is classified as venture growth investor backed and is currently operating.

When was INNOVENTRIC founded?

INNOVENTRIC was founded in 2016. It employs 11 to 50 people.

Where is INNOVENTRIC based?

INNOVENTRIC is headquartered in Rehovot, Israel, in the Middle East region.

How does INNOVENTRIC make money?

One revenue line is on record: medical Device Sales.

Who are INNOVENTRIC's main competitors?

Broad incumbents on record are Edwards Lifesciences, Medtronic and Abbott. Emerging players are Cardiac Dimensions, Polares Medical, Anteris Technologies, Cardiovalve, 4C Medical Technologies, CroíValve and Venus Medtech.

Does INNOVENTRIC have an API?

No public API is recorded for INNOVENTRIC.

What industry is INNOVENTRIC in?

INNOVENTRIC's product category is Transcatheter Heart Valve Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHADAM, Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals